Published: 23 May 2019
Author(s): Arantzazu Barquín-García, Javier Molina-Cerrillo, Pilar Garrido, Daniel Garcia-Palos, Alfredo Carrato, Teresa Alonso-Gordoa
Issue: May 2019
Section: Narrative Review

Over the last decade anticancer treatment has experienced encouraging changes. One of the latest developments is immunotherapy, which is increasingly becoming a mainstay for the treatment of these malignancies. Unlike conventional chemotherapy, immunotherapy enhances anti-tumor immune response by blocking inhibitory immune checkpoints, and allowing our own immune system to fight against the tumor cells, arising as a new and innovative mechanism of action. Therefore, although well tolerated, these drugs have a unique side effect profile and are known to cause immune-related adverse events (irAEs).

Newsletters

Stay informed on our latest news!